PAR OMISSION OF FAILING DATA IN VALIDATION REPORTS
PAR OMISSION OF FAILING DATA IN VALIDATION REPORTS and other violations of Good Manufacturing Practices at the generic pharmaceutical firm resulted in a May 19 warning letter from FDA's Brooklyn District Office. The letter, which cites 14 types of GMP violations involving 22 products, resulted from an inspection carried out at Par's Spring Valley, N.Y. facility between January and May. The Pharmaceutical Basics, Inc. subsidiary regained eligibility for ANDA approvals on Oct. 25, two years to the day after eligibility suspension under FDA's applications integrity policy ("The Pink Sheet" Nov. 1, 1993, In Brief).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth